| Bioactivity | Caloxin 2A1 TFA is an extracellular plasma membrane Ca2+-ATPase (PMCA) peptide inhibitor. Caloxin 2A1 TFA does not affect basal Mg2+-ATPase or Na+-K+-ATPase[1]. | ||||||
| Invitro | Caloxin 2A1 TFA inhibits Ca2+-Mg2+-ATPase in human erythrocyte leaky ghosts, but it does not affect basal Mg2+-ATPase or Na+-K+-ATPase in the ghosts or Ca2+-Mg2+-ATPase in the skeletal muscle sarcoplasmic reticulum. Caloxin 2A1 TFA also inhibits Ca2+-dependent formation of the 140-kDa acid-stable acylphosphate[1].Caloxin 2A1 TFA increases airway smooth muscle cells (ASMCs) apoptosis[2]. | ||||||
| Name | Caloxin 2A1 TFA | ||||||
| Shortening | VSNSNWPSFPSSGGG-NH2 | ||||||
| Formula | C66H92F3N19O24 | ||||||
| Molar Mass | 1592.54 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |